Effect of amyloid-beta oligomers on surface hydrophobicity of human transthyretin protein

Ghadami, Seyyed Abolghasem

Effect of amyloid-beta oligomers on surface hydrophobicity of human transthyretin protein

Document Type : Original Research

Author

Seyyed Abolghasem Ghadami

Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran

Abstract

Transthyretin (TTR) is a highly conserved 55 kDa homotetrameric protein that exists in several vertebrate species including humans, bacteria, nematodes, and plants. Previous studies have shown a direct interaction between TTR and amyloid beta (Aβ) (the causative agent of Alzheimer's disease), which leads to the inhibition of Aβ aggregation, fibrillar destruction, or both. In recent years, evidence has shown that the oligomeric species of Aβ formed by the aggregation process are more toxic than mature fibrils. Studies have shown that such an oligomeric mediator is modulated by interaction with TTR. However, the exact mechanism of binding of Aβ to TTR has not yet been determined. In this study, after the purification of human transthyretin protein, the inhibitory effects of TTR on the formation of Aβ were shown in different ways, and finally, the role of hydrophobicity interactions in the chaperone activity of TTR was investigated with the help of protein surface hydrophobicity (PSH) measurement studies. The Scatchard diagram for quantitative measurement of PSH indicates an increase in the hydrophobicity of TTR after binding to oligomeric forms of Aβ. The results presented in this research provide insight into the nature and interactions involved in the initial stages of fibril formation in Aβ and its interaction with TTR. The results showed that hydrophobic interactions probably play a role in the binding between TTR and Aβ. Considering the similarity of amyloid formation systems, the described findings of this study can provide a deeper understanding of the pathology of amyloid diseases.

Keywords

Neurodegenerative diseases

transthyretin

amyloid fibrils

amyloid beta

Subjects

Molecular biotechnology

[1] M. A. Liz, T. Coelho, V. Bellotti, M. I. Fernandez-Arias, P. Mallaina, and L. Obici. (2020) A Narrative Review of the Role of Transthyretin in Health and Disease, Neurol Ther 9, 395-402.
[2] M. Vieira, and M. J. Saraiva. (2014) Transthyretin: a multifaceted protein, Biomol Concepts 5, 45-54.
[3] T. Giao, J. Saavedra, E. Cotrina, J. Quintana, J. Llop, G. Arsequell, and I. Cardoso. (2020) Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimer's Disease, Int J Mol Sci 21.
[4] R. Costa, F. Ferreira-da-Silva, M. J. Saraiva, and I. Cardoso. (2008) Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor, PLoS One 3, e2899.
[5] S. A. Ghadami, S. Chia, F. S. Ruggeri, G. Meisl, F. Bemporad, J. Habchi, R. Cascella, C. M. Dobson, M. Vendruscolo, T. P. J. Knowles, and F. Chiti. (2020) Transthyretin Inhibits Primary and Secondary Nucleations of Amyloid-beta Peptide Aggregation and Reduces the Toxicity of Its Oligomers, Biomacromolecules 21, 1112-1125.
[6] S. A. Ghadami, F. Bemporad, B. M. Sala, G. Tiana, S. Ricagno, and F. Chiti. (2017) FRET studies of various conformational states adopted by transthyretin, Cellular and Molecular Life Sciences 74, 3577-3598.
[7] M. Cardamone, and N. K. Puri. (1992) Spectrofluorimetric assessment of the surface hydrophobicity of proteins, Biochem J 282 ( Pt 2), 589-593.
[8] M. Möller, and A. Denicola. (2002) Study of protein-ligand binding by fluorescence, Biochemistry and Molecular Biology Education 30, 309-312.
[9] M. R. Krebs, E. H. Bromley, and A. M. Donald. (2005) The binding of thioflavin-T to amyloid fibrils: localisation and implications, Journal of structural biology 149, 30-37.
[10] R. Khurana, C. Coleman, C. Ionescu-Zanetti, S. A. Carter, V. Krishna, R. K. Grover, R. Roy, and S. Singh. (2005) Mechanism of thioflavin T binding to amyloid fibrils, Journal of structural biology 151, 229-238.
[11] N. Rezaei-Ghaleh, H. Ramshini, A. Ebrahim-Habibi, A. A. Moosavi-Movahedi, and M. Nemat-Gorgani. (2008) Thermal aggregation of α-chymotrypsin: role of hydrophobic and electrostatic interactions, Biophysical chemistry 132, 23-32.
[12] S. S. Shahangian, B. Rasti, R. H. Sajedi, R. Khodarahmi, M. Taghdir, and B. Ranjbar. (2011) Artemin as an Efficient Molecular Chaperone, The Protein Journal 30, 549-557.
[13] M. R. Nilsson. (2004) Techniques to study amyloid fibril formation in vitro, Methods 34, 151-160.
[14] V. N. Uversky, and A. L. Fink. (2004) Conformational constraints for amyloid fibrillation: the importance of being unfolded, Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1698, 131-153.
[15] A. M. Landes, S. D. Sperry, M. E. Strauss, and D. S. Geldmacher. (2001) Apathy in Alzheimer's disease, Journal of the American Geriatrics Society 49, 1700-1707.
[16] J. Serot, D. Christmann, T. Dubost, and M. Couturier. (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease, Journal of Neurology, Neurosurgery & Psychiatry 63, 506-508.
[17] D. Jazaj, S. A. Ghadami, F. Bemporad, and F. Chiti. (2019) Probing conformational changes of monomeric transthyretin with second derivative fluorescence, Sci Rep 9, 10988.
[18] S. A. Ghadami, F. Bemporad, B. M. Sala, G. Tiana, S. Ricagno, and F. Chiti. (2017) FRET studies of various conformational states adopted by transthyretin, Cell Mol Life Sci 74, 3577-3598.
[19] S. Conti, X. Li, S. Gianni, S. A. Ghadami, J. Buxbaum, C. Cecchi, F. Chiti, and F. Bemporad. (2014) A complex equilibrium among partially unfolded conformations in monomeric transthyretin, Biochemistry 53, 4381-4392.
[20] M. J. Saraiva. (1995) Transthyretin mutations in health and disease, Hum Mutat 5, 191-196.
[21] C. A. Ribeiro, M. J. Saraiva, and I. Cardoso. (2012) Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide-relevance in Alzheimer's disease.
[22] M. Vieira, and M. J. Saraiva. (2014) Transthyretin: a multifaceted protein, Biomolecular concepts 5, 45-54.